Vaccine Manufacture and Supply – News and Features

New technologies to produce vaccines more safely, quickly and economically than traditional approaches are featured at the New Cells, New Vaccines VII: From Protein to Product international scientific conference.

Scientists at leading public health agencies and research institutes collaborate to develop faster, more reliable flu subtyping methods.

Technology innovation and increasing focus on new vaccine development are likely to revolutionize the vaccine industry from prophylactic to therapeutic vaccines.

Company accelerates the development and manufacturing of cell-based VLP-type vaccines using the MaxCyte Flow Electroporation Technology Platform.

Researchers have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.

UMN Pharma will produce a number of biosimilars using Catalent’s GPEx cell lines.

New and increasingly sophisticated vaccines are taking aim at a broad range of disease-causing pathogens, targeting them with greater effectiveness at lower cost and with improved measures to ensure safety.

Through establishing greater cooperation throughout the developing world on vaccine research and development.

Contract is to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.